Abstract
We recently reported that inhibitors against human dihydroorotate dehydrogenase (DHODH) have broad-spectrum antiviral activities including their inhibitory efficacies on SARS-CoV-2 replication in infected cells. However, there are limited data from clinical studies to prove the application of DHODH inhibitors in Coronavirus disease 2019 (COVID-19) patients. In the present study, we evaluated Leflunomide, an approved DHODH inhibitor widely used as a modest immune regulator to treat autoimmune diseases, in treating COVID-19 disease with a small-scale of patients. Cases of 10 laboratory-confirmed COVID-19 patients of moderate type with obvious opacity in the lung were included. Five of the patients were treated with Leflunomide, and another five were treated as blank controls without a placebo. All the patients accepted standard supportive treatment for COVID-19. The patients given Leflunomide had a shorter viral shedding time (median of 5 days) than the controls (median of 11 days, P = 0.046). The patients given Leflunomide also showed a significant reduction in C-reactive protein levels, indicating that immunopathological inflammation was well controlled. No obvious adverse effects were observed in Leflunomide-treated patients, ...Continue Reading
References
Oct 29, 2000·Annals of the Rheumatic Diseases·F C Breedveld, J M Dayer
May 20, 2011·RNA Biology·Mark R DenisonRalph S Baric
Feb 26, 2015·Expert Review of Clinical Pharmacology·Yara Dadalti Fragoso, Joseph Bruno Bidin Brooks
Mar 5, 2016·Nature·Travis K WarrenSina Bavari
Oct 11, 2016·European Journal of Medicinal Chemistry·Anju SinghNasimul Hoda
Jan 27, 2017·Journal of Medicinal Chemistry·Dustin SiegelRichard L Mackman
Jan 28, 2020·Lancet·Chaolin HuangBin Cao
Feb 9, 2020·Nature Reviews. Rheumatology·Eva Schrezenmeier, Thomas Dörner
Mar 17, 2020·International Journal of Antimicrobial Agents·Christian A DevauxDidier Raoult
Mar 19, 2020·The New England Journal of Medicine·Bin CaoChen Wang
Apr 11, 2020·The New England Journal of Medicine·Jonathan GreinTimothy Flanigan
Apr 16, 2020·Science·Stephen M KisslerMarc Lipsitch
Apr 30, 2020·Engineering·Qingxian CaiLei Liu
May 3, 2020·Science·Wanchao YinH Eric Xu
May 8, 2020·The New England Journal of Medicine·Joshua GelerisNeil W Schluger
May 20, 2020·Lancet·Yeming WangChen Wang
May 24, 2020·The New England Journal of Medicine·John H BeigelUNKNOWN ACTT-1 Study Group Members
Citations
Dec 4, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nicholas J DeVito
Jan 9, 2021·The Journal of General Virology·Yao LiXiulong Xu
Feb 7, 2021·Annals of the Rheumatic Diseases·Alessia AlunnoXavier Mariette
Feb 17, 2021·Annals of the Rheumatic Diseases·Alessia AlunnoPedro M Machado
Oct 15, 2020·Viruses·Jiongjiong WangXiulong Xu
Jun 12, 2021·Bioorganic & Medicinal Chemistry Letters·Milena M PetrovićMilan D Joksović
Jul 5, 2021·Current Opinion in Virology·Julien SourimantRichard K Plemper
Jun 11, 2021·European Journal of Pharmacology·Hardeep KaurBikash Medhi
Jul 19, 2021·Journal of Clinical Epidemiology·Kimia HonarmandBram Rochwerg
Jul 13, 2021·Acta Pharmaceutica Sinica. B·Rong XiangShibo Jiang
May 31, 2021·Clinical Rheumatology·Behnaz YousefghahariHemmat Gholinia
Nov 1, 2021·Drug Discovery Today·Jun-Lin YuGuo-Bo Li